Movement Alert｜RemeGen Rises 5.13% in Regular Trading, FDA Greenlights Telitacicept Phase II Trial for IgA Nephropathy in the US

Market Focus05-29

On May 29, RemeGen rose 5.13% in regular trading, trading at HKD 83.15 per share, with trading volume of HKD 247 million. The stock was buoyed by a series of positive clinical developments and broad biotech sector strength.

On the news front, the company announced it received FDA approval to conduct a Phase II clinical trial of Telitacicept for the treatment of IgA nephropathy in the United States. This milestone follows the recent publication of Telitacicept Phase III clinical results for IgA nephropathy in the New England Journal of Medicine, reinforcing the drug's global development trajectory. The company also recently reported first patient enrollment in Phase III trials for RC148 in advanced squamous NSCLC and Phase I/IIa trials for RC288 in advanced solid tumors, signaling continued pipeline momentum.

The broader Biotechnology sector exhibited strong gains, with Innovent Bio up 11.02%, Akeso up 6.79%, 3SBIO up 7.94%, SKB Bio up 4.34%, and BeiGene up 1.31%, reflecting sector-wide positive sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1170618499?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-29 13:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1170618499","market":"us","top_or_hot":-1,"title":"Movement Alert｜RemeGen Rises 5.13% in Regular Trading, FDA Greenlights Telitacicept Phase II Trial for IgA Nephropathy in the US","media":"Market Focus","content":"<p><p>On May 29, RemeGen rose 5.13% in regular trading, trading at HKD 83.15 per share, with trading volume of HKD 247 million. The stock was buoyed by a series of positive clinical developments and broad biotech sector strength.</p><p>On the news front, the company announced it received FDA approval to conduct a Phase II clinical trial of Telitacicept for the treatment of IgA nephropathy in the United States. This milestone follows the recent publication of Telitacicept Phase III clinical results for IgA nephropathy in the New England Journal of Medicine, reinforcing the drug's global development trajectory. The company also recently reported first patient enrollment in Phase III trials for RC148 in advanced squamous NSCLC and Phase I/IIa trials for RC288 in advanced solid tumors, signaling continued pipeline momentum.</p><p>The broader Biotechnology sector exhibited strong gains, with Innovent Bio up 11.02%, Akeso up 6.79%, 3SBIO up 7.94%, SKB Bio up 4.34%, and BeiGene up 1.31%, reflecting sector-wide positive sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜RemeGen Rises 5.13% in Regular Trading, FDA Greenlights Telitacicept Phase II Trial for IgA Nephropathy in the US</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜RemeGen Rises 5.13% in Regular Trading, FDA Greenlights Telitacicept Phase II Trial for IgA Nephropathy in the US\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-29 13:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 29, RemeGen rose 5.13% in regular trading, trading at HKD 83.15 per share, with trading volume of HKD 247 million. The stock was buoyed by a series of positive clinical developments and broad biotech sector strength.</p><p>On the news front, the company announced it received FDA approval to conduct a Phase II clinical trial of Telitacicept for the treatment of IgA nephropathy in the United States. This milestone follows the recent publication of Telitacicept Phase III clinical results for IgA nephropathy in the New England Journal of Medicine, reinforcing the drug's global development trajectory. The company also recently reported first patient enrollment in Phase III trials for RC148 in advanced squamous NSCLC and Phase I/IIa trials for RC288 in advanced solid tumors, signaling continued pipeline momentum.</p><p>The broader Biotechnology sector exhibited strong gains, with Innovent Bio up 11.02%, Akeso up 6.79%, 3SBIO up 7.94%, SKB Bio up 4.34%, and BeiGene up 1.31%, reflecting sector-wide positive sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1170618499","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1170618499","pubTimestamp":1780032797,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 29, RemeGen rose 5.13% in regular trading, trading at HKD 83.15 per share, with trading volume of HKD 247 million. The stock was buoyed by a series of positive clinical developments and broad...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"动静提示|RemeGen常规交易涨5.13%FDA批准Telitacicept在美治疗IgA肾病II期试验","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1},"content_text":"On May 29, RemeGen rose 5.13% in regular trading, trading at HKD 83.15 per share, with trading volume of HKD 247 million. The stock was buoyed by a series of positive clinical developments and broad biotech sector strength.On the news front, the company announced it received FDA approval to conduct a Phase II clinical trial of Telitacicept for the treatment of IgA nephropathy in the United States. This milestone follows the recent publication of Telitacicept Phase III clinical results for IgA nephropathy in the New England Journal of Medicine, reinforcing the drug's global development trajectory. The company also recently reported first patient enrollment in Phase III trials for RC148 in advanced squamous NSCLC and Phase I/IIa trials for RC288 in advanced solid tumors, signaling continued pipeline momentum.The broader Biotechnology sector exhibited strong gains, with Innovent Bio up 11.02%, Akeso up 6.79%, 3SBIO up 7.94%, SKB Bio up 4.34%, and BeiGene up 1.31%, reflecting sector-wide positive sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1170618499","isCrawlerRequest":true}